ライフサイエンスコーパス: serotonin transporter

1 postsynaptic D2 antagonist, and inhibitor of serotonin transporter.

2 ectual disabilities the functionality of the serotonin transporter.

3 rmalin-induced pain, as did mice lacking the serotonin transporter.

4 abolism), serotonin receptor 5-HT4, or mouse serotonin transporter.

5 ts reuptake at dopamine, norepinephrine, and serotonin transporters.

6 ine D2/D3 receptors ([(11)C]raclopride), and serotonin transporter (11)C-N,N-dimethyl-2-(-2-amino-4-c

7 The serotonin transporter 5-HTTLPR genotype has been found t

8 The gene encoding the serotonin transporter (5-HTT) contains a regulatory vari

9 SIDS).Mice with a targeted disruption of the serotonin transporter (5-HTT) develop in the presence of

10 gical signaling in mouse models of disrupted serotonin transporter (5-HTT) function, a risk factor fo

11 A polymorphism in the human serotonin transporter (5-HTT) gene is implicated in susc

12 ic blockade of monoamine oxidase A (MAOA) or serotonin transporter (5-HTT) has antidepressant and anx

13 The serotonin transporter (5-HTT) is a key target for select

14 Because the serotonin transporter (5-HTT) is an important regulator

15 caine self-administration at a high level of serotonin transporter (5-HTT) occupancy with no detectab

16 The serotonin transporter (5-HTT) plays a critical role in r

17 unoreactive (IR) with antibodies against the serotonin transporter (5-HTT) protein were widely distri

18 th are involved in serotonin synthesis), and serotonin transporter (5-HTT) were measured in the ventr

19 imaging with a radiotracer specific for the serotonin transporter (5-HTT), (11)C-McN5652, we found t

20 genetic and environmental factors, including serotonin transporter (5-HTTLPR) genotype.

21 variations in the 5-hydroxytryptamine (5-HT; serotonin) transporter (5-HTT) gene are associated with

22 structural variants of the gene encoding the serotonin transporter [5-hydroxytryptamine transporter (

23 corresponding residues (R104E/E493R) in the serotonin transporter also rescues [(3)H](S)-citalopram

24 levels leading to the down-regulation of the serotonin transporter and a variety of 5-HT receptors, i

25 MOD-5, the C. elegans orthologue of the serotonin transporter and cellular target of citalopram,

26 ed by platelet serotonin accumulated via the serotonin transporter and could be antagonized using ser

27 be single molecular interactions between the serotonin transporter and MFZ2-12 (a potent cocaine anal

28 functionally important Cl(-) binding site in serotonin transporter and other Cl(-)-dependent transpor

29 tion between microRNA 135 (miR135), and both serotonin transporter and serotonin receptor-1a transcri

30 involved in the pathogenesis of PAH such as serotonin transporter and tenascin-C was elevated in dis

31 18)F]MPPF, two PET radiotracers, marking the serotonin transporter and the 5-HT1AR, respectively.

32 Tyrosines 95 and 175 in the human serotonin transporter and the corresponding phenylalanin

33 ative affinity of the antidepressant for the serotonin transporter and to assess whether concomitant

34 HSCs were shown to express a functional serotonin transporter and to participate in both active

35 May, 2016, were studied with tracers for the serotonin transporter and vesicular monoamine transporte

36 hibits both the dopamine transporter and the serotonin transporter, and simple chemical modifications

37 and interactions with dopamine transporter, serotonin transporter, and vesicular monoamine transport

38 erotonin reuptake inhibitors targeting brain serotonin transporters are first-line treatments for bip

39 MRN for tryptophan hydroxylase-2 (Tph2), the serotonin transporter, as well as 5-HT1A and 5-HT1B rece

40 croscopy to study the diffusion of the human serotonin transporter at the ER and the plasma membrane.

41 There was no association between raphe serotonin transporter availability and fatigue, depressi

42 sease subgroup had significantly lower raphe serotonin transporter availability but less severe stria

43 Parkinson's disease had significantly lower serotonin transporter availability in the brainstem raph

44 Increased serotonin transporter availability in the patients with

45 on's disease patients and that reduced raphe serotonin transporter availability is associated with th

46 s and release, are downregulated in SAD, and serotonin transporter availability might be increased; h

47 Raphe serotonin transporter availability over the entire Parki

48 In tremulous patients, raphe serotonin transporter availability was also associated w

49 d [11C]DASB binding potential as an index of serotonin transporter availability were acquired during

50 hy, markers of dopamine storage capacity and serotonin transporter availability, to investigate wheth

51 nding in the brainstem raphe nuclei reflects serotonin transporter availability.

52 puted tomography is a marker of dopamine and serotonin transporter availability.

53 Low midbrain serotonin transporter binding appears to be related to t

54 Future studies should investigate midbrain serotonin transporter binding as a predictor of suicidal

55 nt with postmortem work showing low midbrain serotonin transporter binding capacity in depressed suic

56 There was no difference in serotonin transporter binding comparing all depressed su

57 pression and not due to its direct effect on serotonin transporter binding in adulthood.

58 We have also reported low in vivo serotonin transporter binding in major depressive disord

59 Depressed suicide attempters had lower serotonin transporter binding in midbrain compared with

60 ding, VMAT2 binding, (18)F-FDOPA uptake, and serotonin transporter binding in multiple brain regions

61 rgic projections together with extrastriatal serotonin transporter binding in Parkinson disease.

62 ehavior and completed suicide, including low serotonin transporter binding in postmortem studies of c

63 Serotonin transporter binding in the cortex did not diff

64 rkinson's disease had significantly elevated serotonin transporter binding in the hypothalamus (compa

65 manifest Parkinson's disease show increased serotonin transporter binding in the striatum, brainstem

66 We quantified regional brain serotonin transporter binding in vivo in depressed suici

67 Serotonin transporter binding potential (f(1)B(max)/K(d)

68 Serotonin transporter binding potential (f(1)B(max)/K(d)

69 There was no difference in serotonin transporter binding potential by genotype in h

70 sion who attempt suicide have lower midbrain serotonin transporter binding potential compared with th

71 region (F1,10 = 0.83; P = .38), and midbrain serotonin transporter binding potential did not predict

72 Serotonin transporter binding potential differed signifi

73 Objectives: To determine whether serotonin transporter binding potential in the lower mid

74 el-based analysis localized further relative serotonin transporter binding reductions in the cingulat

75 atients with fatigue had significantly lower serotonin transporter binding than patients without fati

76 onin transporter promoter gene (5-HTTLPR) on serotonin transporter binding using in vivo imaging tech

77 In vivo brain serotonin transporter binding was measured using positro

78 11)C]DASB to quantify in vivo regional brain serotonin transporter binding.

79 Lower serotonin transporter BP(1) in bipolar depression overla

80 s with bipolar disorder had 16% to 26% lower serotonin transporter BP(1) in the midbrain, amygdala, h

81 allelic 5-HTTLPR genotypes were unrelated to serotonin transporter BP(1).

82 e inhibition, excellent selectivity over the serotonin transporter, but no selectivity over the dopam

83 onin transporter occupancy prevented similar serotonin transporter calculations.

84 ng PET, we assessed whether dopaminergic and serotonin transporter changes are similar in LRRK2 mutat

85 factor (BDNF), reduced Glut4, with unchanged serotonin transporter concentrations were noted in (F) (

86 y; on the other candidate genes, such as the serotonin transporter, continue to dominate in genetic s

87 er was significantly higher than that of the serotonin transporter, despite similar in vitro potencie

88 upport the hypothesis that inhibition of the serotonin transporter during neonatal life by an SSRI is

89 necessary to confirm that inhibition of the serotonin transporter during the neonatal period is suff

90 Participants with low serotonin transporter expression had higher signal-to-no

91 This indicates that serotonin transporter expression, eventually in combinat

92 extent of down-regulation is potentiated by serotonin transporter function (IC50 of 2.3 +/- 1.0 muM,

93 associations between genetic variability in serotonin transporter function and stress-related psycho

94 patients seem to have upregulation of brain serotonin transporter function at the early phase of the

95 us underlying interindividual differences in serotonin transporter function in humans.

96 reuptake inhibitor, fluvoxamine, to inhibit serotonin transporter function in ovariectomized rats.

97 ch locus, supporting the notion of increased serotonin transporter functioning being pathogenetically

98 lymorphisms (5-HTTLPR and STin2 VNTR) of the serotonin transporter gene (5-HTT), we find strong evide

99 46)- which directs reduced expression of the serotonin transporter gene (5-HTT).

100 Polymorphisms in the promoter region of the serotonin transporter gene (5-HTTLPR) and exposure to ea

101 A promoter polymorphism in the serotonin transporter gene (5-HTTLPR) has been reported

102 a polymorphism in the promoter region of the serotonin transporter gene (5-HTTLPR) offering equivocal

103 a polymorphism in the promoter region of the serotonin transporter gene (5-HTTLPR), we found that ind

104 ed the hypothesis that a polymorphism in the serotonin transporter gene (locus, SLC6A4; variant, sero

105 etic variation in the promoter region of the serotonin transporter gene (serotonin transporter-linked

106 Polymorphisms of the serotonin transporter gene (SERT) have been associated w

107 udies have reported associations between the serotonin transporter gene (SLC6A4) and alcohol, heroin,

108 hism (5HTTLPR) in the promoter region of the serotonin transporter gene (SLC6A4) and exposure to chil

109 We show that variants at the serotonin transporter gene (SLC6A4) and serotonin 2A rec

110 ects in two candidate genes of interest--the serotonin transporter gene (SLC6A4) and the integrin bet

111 rphisms in the repeat upstream region of the serotonin transporter gene (SLC6A4) are associated with

112 R polymorphism in the promoter region of the serotonin transporter gene (SLC6A4) has been found to mo

113 The serotonin transporter gene (SLC6A4) is a strong autism c

114 nalyses of common functional variants of the serotonin transporter gene (SLC6A4), a long-standing OCD

115 rphism located in the promoter region of the serotonin transporter gene (SLC6A4), is implicated in sp

116 he well-studied 5-HTTLPR polymorphism in the serotonin transporter gene (SLC6A4).

117 iry: variation in the promoter region of the serotonin transporter gene (SLC6A4; also known as 5-HTT)

118 The lower expressing allele of the serotonin transporter gene 5' promoter region (5-HTTLPR)

119 idence of association between alleles of the serotonin transporter gene and pulmonary hypertension wa

120 e-environment interactions (GxE) between the serotonin transporter gene and stress on risk of depress

121 entifying two common genetic variants of the serotonin transporter gene and their association with in

122 Participants with a variant at the serotonin transporter gene contribute more, leading to g

123 The serotonin transporter gene has previously been implicate

124 Additionally, allelic variation in the serotonin transporter gene is associated with prevalence

125 Polymorphisms in the serotonin transporter gene may be a key risk factor as w

126 igates whether a genetic polymorphism of the serotonin transporter gene moderates susceptibility to a

127 e is associated with brain morphology is the serotonin transporter gene polymorphism within the promo

128 rs1042173-TT (SLC6A4-LL/TT) genotypes in the serotonin transporter gene predicted a significant reduc

129 d that increased promoter methylation of the serotonin transporter gene predicted increased threat-re

130 re we show that a common polymorphism in the serotonin transporter gene relates to an accurate and ro

131 R, a functional promoter polymorphism of the serotonin transporter gene SLC6A4, influences cerebral c

132 The HTTLPR, a functional polymorphism of the serotonin transporter gene solute carrier family 6 (neur

133 s, carrying at least one short allele of the serotonin transporter gene was associated with a 26% hig

134 Individuals with 1 or 2 short alleles of the serotonin transporter gene were at higher risk for an in

135 We investigated polymorphic variation of the serotonin transporter gene, a biological candidate for p

136 Variation at the serotonin transporter gene, SLC6A4, has been associated

137 methylation of the proximal promoter of the serotonin transporter gene, which predicts greater incre

138 in the transcriptional control region of the serotonin transporter gene, which renders carriers of th

139 Variation in the serotonin transporter gene-linked polymorphic region (5-

140 ncreased in short-allele (s) carriers of the serotonin transporter gene.

141 ol) carried at least one short allele of the serotonin transporter gene.

142 renaline transporter (NAT) gene, and not the serotonin transporter genes, in dopaminergic cells, whic

143 s meta-analysis yielded no evidence that the serotonin transporter genotype alone or in interaction w

144 so differentially affected, as a function of serotonin transporter genotype, functional connectivity

145 Human serotonin transporter (hSERT) activity expressed in HeLa

146 tagonists with and without concomitant human serotonin transporter (hSerT) activity.

147 ridinium (MPP(+)) as reporters for the human serotonin transporter (hSERT) in single cells.

148 spite the well-established role of the human serotonin transporter (hSERT) in the treatment of depres

149 Serotonin (5-HT) uptake by the human serotonin transporter (hSERT) is driven by ion gradients

150 The human serotonin transporter (hSERT) is responsible for the ter

151 e photoaffinity ligands (PALs) for the human serotonin transporter (hSERT) were synthesized based on

152 SLC6 family of proteins, including the human serotonin transporter (hSERT), utilize Na(+), Cl(-), and

153 ermined X-ray crystal structure of the human serotonin transporter (hSERT).

154 Serotonin transporter immunohistochemistry or cytochrome

155 somata, or in norepinephrine transporter or serotonin transporter immunoreactivity.

156 lain discrepant in vivo findings quantifying serotonin transporter in depression.

157 t in the relative importance of dopamine and serotonin transporters in the abuse-related-effects of c

158 ypoxic or transgenic mice overexpressing the serotonin-transporter in SMCs (SM22-5HTT+ mice).

159 thesized and characterized as norepinephrine/serotonin transporter inhibitors.

160 E2, the density of fibers immunoreactive for serotonin transporter innervating the auditory midbrain

161 Although residues in the human serotonin transporter involved in direct Cl(-) coordinat

162 Serotonin transporter knockout (SERT-/-) mice are extens

163 s in humans mirror the phenotypic effects of serotonin transporter knockout in mice, highlighting the

164 he amygdala and cingulate cortex between the serotonin transporter knockout mouse, a genetic animal m

165 Parkinson's disease; and (ii) whether raphe serotonin transporter levels correlate with severity of

166 rs increased SLC6A4 transcription, increased serotonin transporter levels in brain and other tissues

167 The serotonin transporter ligand (11)C-3-amino-4(2-dimethyla

168 e investigated with SPECT using the dopamine/serotonin transporter ligand (123)I-N-omega-fluoropropyl

169 pothesis: 1) observational studies about the serotonin transporter linked polymorphic region (5-HTTLP

170 ing the report of an interaction between the serotonin transporter linked polymorphic region (5-HTTLP

171 ied the influence of genetic variance in the serotonin transporter linked polymorphic region (5-HTTLP

172 Genetic variation at the serotonin transporter-linked polymorphic region (5-HTTLP

173 Here, we postulated that the serotonin transporter-linked polymorphic region (5-HTTLP

174 Additionally, we considered serotonin transporter-linked polymorphic region (5-HTTLP

175 er region of the serotonin transporter gene (serotonin transporter-linked polymorphic region [5-HTTLP

176 less than 150 nucleotides centromeric of the serotonin transporter-linked polymorphic region indel kn

177 1A (5-HT1A) polymorphism at -1019C>G and the serotonin transporter LS polymorphism, have been reporte

178 ta suggest that differential function of the serotonin transporter may mediate differential response

179 ed decreases in tryptophan hydroxylase 2 and serotonin transporter mRNA in the dorsal raphe dorsalis

180 Average dopamine and serotonin transporter occupancies increased with increas

181 Mean dopamine and serotonin transporter occupancies were 33% +/- 11% and 2

182 Dopamine and serotonin transporter occupancies were estimated from PE

183 cupancy was extrapolated (85%); however, low serotonin transporter occupancy prevented similar seroto

184 f SEP-225289 to investigate its dopamine and serotonin transporter occupancy.

185 and from mice with PH induced by hypoxia or serotonin-transporter overexpression (SM22-5HTT(+) mice)

186 nomethyl-phenylsulfaryl)-benzonitrile (DASB) serotonin transporter PET imaging was performed in a sub

187 onin signaling in the form of a common human serotonin transporter polyadenylation polymorphism (STPP

188 Furthermore, we show that the serotonin transporter polyadenylation profile associated

189 When infant genotype for serotonin transporter polymorphism was taken into accoun

190 and 145 control) was genotyped for a common serotonin transporter polymorphism.

191 association of the STin2 and/or the 5-HTTLPR serotonin transporter polymorphisms in adult males with

192 elationship of a functional variation of the serotonin transporter promoter gene (5-HTTLPR) on seroto

193 Conversely, the serotonin transporter promoter polymorphism (5-HTTLPR) s

194 A functional serotonin transporter promoter polymorphism, HTTLPR, alt

195 Associations of serotonin transporter promoter polymorphisms and bipolar

196 hypothesis that the S allele of the 5-HTTLPR serotonin transporter promoter region is associated with

197 was no association between genotypes of the serotonin transporter promoter region polymorphism and s

198 of serotonin and serotonergic receptors are serotonin transporter protein (SERT or soluble carrier p

199 of a genetic polymorphism (5-HTTLPR) in the serotonin transporter protein gene on the likelihood tha

200 ions in TnaT-D268S, in wild type TnaT and in serotonin transporter provide direct evidence for the in

201 phenylsulfanyl)- benzonitrile ([11C]DASB), a serotonin transporter radioligand.

202 ing the dopamine transporter (DAT(-/-)), the serotonin transporter (SERT(-/-)), or both (DAT(-/-)SERT

203 of the alternate conformation in a mammalian serotonin transporter (SERT) (a member of the same trans

204 Serotonin transporter (SERT) and 5-HT(2A) receptor avail

205 The serotonin transporter (SERT) and other monoamine transpo

206 ion tomography for two serotonergic markers: serotonin transporter (SERT) and serotonin 1A (5-HT1A) r

207 ial smooth muscle cell proliferation via the serotonin transporter (SERT) and serotonin can induce pu

208 The serotonin transporter (SERT) and the norepinephrine tran

209 y measure the interaction forces between the serotonin transporter (SERT) and the S- and R-enantiomer

210 f juvenile grasshopper mice labeled with the serotonin transporter (SERT) antibody, revealing a strik

211 Inhibitors of the serotonin transporter (SERT) are widely used antidepress

212 We have developed a homology model for the serotonin transporter (SERT) based on the crystal struct

213 This study compared regional brain serotonin transporter (SERT) binding between nine PR and

214 ptoms was associated with change in cerebral serotonin transporter (SERT) binding following intervent

215 iencephalon, which may reflect predominantly serotonin transporter (SERT) binding.

216 The serotonin transporter (SERT) controls synaptic serotonin

217 ty of using (11)C-DASB for quantification of serotonin transporter (SERT) density and affinity in viv

218 lthio)benzylamine ((11)C-HOMADAM) imaging of serotonin transporter (SERT) density in healthy control

219 Mutations in the C terminus of the serotonin transporter (SERT) disrupt folding and export

220 of intracellular solute-binding to the human serotonin transporter (SERT) expressed in HEK-293 cells.

221 panes 1-4 were synthesized as ligands of the serotonin transporter (SERT) for use as positron emissio

222 Export of the serotonin transporter (SERT) from the endoplasmic reticu

223 ould be via HPA axis-dependent impairment of serotonin transporter (SERT) function, the high-affinity

224 obesity, potentially attributed to a reduced serotonin transporter (SERT) function.

225 k and reports on the optimization of DAT and serotonin transporter (SERT) functional assays, as well

226 identified genetic interactions between the serotonin transporter (SERT) gene and ITGB3, which encod

227 The s/l promoter polymorphism in the serotonin transporter (SERT) gene moderates both trait e

228 Antagonist dissociation experiments on the serotonin transporter (SERT) have also unveiled the exis

229 t years, a number of PET studies imaging the serotonin transporter (SERT) have been used and provided

230 opane (betaFEpZIENT, 1) was synthesized as a serotonin transporter (SERT) imaging agent for both posi

231 rivatives 40-42) were prepared and tested as serotonin transporter (SERT) imaging agents.

232 oimaging, and genetic findings implicate the serotonin transporter (SERT) in autism spectrum disorder

233 PET of the serotonin transporter (SERT) in the brain is a useful to

234 Fluoxetine, a serotonin transporter (SERT) inhibitor, produced CPP in

235 The serotonin transporter (SERT) is a major regulator of ser

236 Serotonin transporter (SERT) is a transmembrane transpor

237 The serotonin transporter (SERT) is an integral membrane pro

238 Serotonin transporter (SERT) is only weakly expressed in

239 The serotonin transporter (SERT) is responsible for reuptake

240 Serotonin transporter (SERT) is responsible for reuptake

241 Serotonin transporter (SERT) is responsible for the re-u

242 Serotonin transporter (SERT) is the main target for wide

243 The serotonin transporter (SERT) is the primary target for a

244 The serotonin transporter (SERT) is the principal mechanism

245 Wild type and serotonin transporter (SERT) knockout mice underwent CR

246 ocampal brain slices from wild-type rats and serotonin transporter (SERT) knockout mice.

247 opane (ZIENT), is a high affinity, selective serotonin transporter (SERT) ligand that has shown promi

248 The serotonin transporter (SERT) maintains serotonergic neur

249 rotonin (5-HT) into neurons and other cells, serotonin transporter (SERT) modulates the action of 5-H

250 rported anti-addiction properties, inhibited serotonin transporter (SERT) noncompetitively by decreas

251 opiate withdrawal, has been shown to inhibit serotonin transporter (SERT) noncompetitively, in contra

252 The serotonin transporter (SERT) on the plasma membrane is t

253 This 5-HT signal was not potentiated by the serotonin transporter (SERT) or the noradrenaline transp

254 The serotonin transporter (SERT) plays a critical role in re

255 Serotonin transporter (SERT) plays a critical role in re

256 Reduced expression of the serotonin transporter (SERT) promotes anxiety and cocain

257 lytic method to derive accurate and reliable serotonin transporter (SERT) receptor parameters with (1

258 The serotonin transporter (SERT) regulates neurotransmission

259 The serotonin transporter (SERT) terminates neurotransmissio

260 The serotonin transporter (SERT) terminates serotonergic neu

261 The serotonin transporter (SERT) terminates serotonergic sig

262 The serotonin transporter (SERT) was measured using immunohi

263 ability in IBS-D including a decrease in the serotonin transporter (SERT) which is also seen followin

264 zing enzyme tryptophan hydroxylase (TPH) and serotonin transporter (SERT) with semiquantitative immun

265 lore structure-activity relationships at the serotonin transporter (SERT), a series of (+/-)-4- and 5

266 isms regulating disulfide bond formation for serotonin transporter (SERT), an oligomeric glycoprotein

267 finities for the dopamine transporter (DAT), serotonin transporter (SERT), and norepinephrine transpo

268 bind to the dopamine transporter (DAT), the serotonin transporter (SERT), and the norepinephrine tra

269 cocaine: the dopamine transporter (DAT), the serotonin transporter (SERT), and the norepinephrine tra

270 f its DAT affinity were only observed at the serotonin transporter (SERT), dopamine D2-like, and sigm

271 how SSRIs, which inhibit the plasma membrane serotonin transporter (SERT), modulate hemostasis.

272 n, (123)I-FP-CIT has modest affinity for the serotonin transporter (SERT), predominantly represented

273 nity for DAT and robust selectivity over the serotonin transporter (SERT), whereas affinity improved

274 Rodents exposed to serotonin transporter (SERT)-inhibiting antidepressants

275 d this approach on the cocaine-sensitive rat serotonin transporter (SERT).

276 he norepinephrine transporter (NET) over the serotonin transporter (SERT).

277 ds with high affinity and selectively to the serotonin transporter (SERT).

278 affinity and selectivity to the human brain serotonin transporter (SERT).

279 istal colon due to an impairment/loss in the serotonin transporter (SERT).

280 llular serotonin (5-HT) by the high-affinity serotonin transporter (SERT).

281 ission is modulated by the membrane-embedded serotonin transporter (SERT).

282 The serotonin transporter (SERT, SLC6A4) in the platelet pla

283 subsequently causes the translocation of the serotonin transporter (SERT, SLC6A4) to the synaptic ter

284 The serotonin transporter (SERT/SLC6A4) has a rich pharmacol

285 the C terminus in supporting folding of the serotonin transporter (SERT; SLC6A4).

286 Parametric imaging of serotonin transporters (SERT) with 11C-labeled 3-amino-4

287 s (K(i) = 1.81 nM) with DAT selectivity over serotonin transporters (SERT; 989-fold), norepinephrine

288 Using immunostaining for the serotonin transporter, SERT, we describe the complete pa

289 s serotonergic [i.e., immunopositive for the serotonin transporter; SERT].

290 RH, the mineralocorticoid receptor (MR), the serotonin transporter (Serta) or GR itself.

291 Channel properties are also attributed to serotonin transporters (SERTs); however, SERT regulation

292 The serotonin transporter (SLC6A4) has been associated with

293 ential interactions between these factors on serotonin transporter (slc6a4) mRNA expression, we inves

294 ters of the SLC6 family, including the human serotonin transporter (SLC6A4), is critical for efficien

295 onferring susceptibility to ASD are PTEN and Serotonin transporter (SLC6A4).

296 norepinephrine transporter (SLC6A2, NET) and serotonin transporter (SLC6A4, SERT) genes and remission

297 f the maternal polymorphism, 5HTTLPR, in the serotonin transporter, SLC6A4, coupled with prenatal str

298 activation of p38alpha MAPK translocated the serotonin transporter to the plasma membrane and increas

299 ubstituents on the 7-position with the human serotonin transporter Tyr175 versus dopamine transporter

300 and intermediate, but not low, affinity for serotonin transporter were associated with upper gastroi